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Abstract The purpose of this ethics approved trial was to
correlate quantitative MRI with functional abilities in both
ambulant and non-ambulant Duchenne muscular dystrophy
(DMD). Twenty patients with genetically confirmed DMD
were recruited. Physical assessment was performed using
the motor function measurement (MFM) scale. Axial 3T
MRI scans of the thighs were acquired using T1-weighted
in- and opposed-phase images (TR = 20 ms, TE1 = 2.45 ms,
TE2 = 3.68 ms, flip angle = 15) to calculate the relative
fat fraction according to the two-point Dixon method in
the knee extensors, flexors, and adductor muscles. The
average MFM was 65.3 % and correlated negatively to age
(r2 = 0.60). Overall mean fat fraction correlated positively
to age (r2 = 0.51–0.64). An average of 5 % increase in
mean fat fraction per year was calculated. Mean fat fraction
of the quadriceps showed a high negative correlation
(r2 = 0.93) to the D1 (standing position and transfers)
component of the MFM. A cutoff for mean fat fraction of
50 % predicted loss of ambulation with a sensitivity of
100 % and a specificity of 91 %. Therefore, quantitative
muscle MRI seems to be a promising endpoint for short
clinical trials evaluating the effect of newer treatments on
the time of loss of ambulation in DMD.
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Abbreviations
DMD Duchenne muscular dystrophy
F Fat
FF Fat fraction
MRI Magnetic resonance imaging
MFM Motor function measurement
qMRI Quantitative magnetic resonance imaging
ROI Regions of interest
TE Echo time
TR Repetition time
W Water
Introduction
Duchenne muscular dystrophy (DMD) is a recessive
X-linked disease of childhood and the most common
pediatric muscular dystrophy, affecting about 1 in every
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3,500 male births. The disease is caused by loss of function
mutations in the dystrophin gene located on the X-chro-
mosome (Xp21). Mutations lead to the absence of or
truncation in the protein dystrophin, an important structural
component of the muscle cell membrane: this abnormality
results in structural fragility, membrane permeability,
metabolic crisis, and progressive myocyte degeneration.
Mutations in the DMD gene result in either Duchenne
muscular dystrophy, the milder Becker muscular dystro-
phy, or X-linked dilated cardiomyopathy [1]. Boys with
DMD experience a progressive loss of strength and func-
tion that leads to wheelchair dependence, cardiorespiratory
compromise, and early death. Recently, several therapeutic
trials with promising results have been published [2, 3].
However, biomarkers and outcome measures, especially
for short-term effects, are still largely lacking.
Loss of independent ambulation has a large impact on
the daily life of the patient as well as the supporting family
and is one of the major factors influencing morbidity. It
would therefore be helpful to predict the time until the loss
of ambulation to give the patient and his caregivers suffi-
cient time to adapt their lifestyle and surroundings. Trials
to establish clinical measurements as prognostic parame-
ters were recently conducted [4], however most clinical
parameters show a high observer dependency.
As a result, quantitative MRI (qMRI) of skeletal muscles
has been introduced in patients with neuromuscular dis-
eases, especially in patients with DMD [5, 6] and has been
shown to provide excellent correlation to clinical parame-
ters in several diseases [7–9].
Most trials in patients with DMD, however, rely on
semiquantitative visual scores to evaluate disease pro-
gression [10, 11]. In a study on 20 DMD patients, we
compared qMRI of the fat fraction in diseased muscles
with established clinical parameters.
Materials and methods
Twenty patients with genetically confirmed DMD were
recruited. Written informed consent was obtained from all
patients or their caretakers. The local ethics committee
approved all measurements.
Physical assessment was performed by two physiother-
apists (T.W. and R.G.) in consensus using the motor
function measurement (MFM) scale, covering the whole
range of abilities in both ambulant and non-ambulant
patients. This scale comprises items from the following
three dimensions: standing position and transfers (D1),
axial and proximal motor function (D2), and distal motor
function (D3). MFM has been shown to have a high inter-
rater reliability, does not require any special equipment and
is well tolerated by patients [12]. Both evaluators had
received special training in MFM evaluation in Lyon,
France, 3 years before and have performed MFM evalua-
tions regularly since.
All MRIs were performed on a 3 Tesla scanner (Mag-
netom Verio, Siemens Healthcare, Erlangen, Germany),
with two 16-element body array coils and a spine coil. One
operator with more than 10 years experience in research
MRI performed all exams according to a pre-specified
protocol. Localization comprised a series of scout images
in three orthogonal directions and additional scout images
parallel and orthogonal to the right/left femur in 14/6 cases,
respectively (depending on patient), as well as scout ima-
ges through the hip and knee joint space. In the case of
atypical patient positioning due to contractions, additional
localizers were acquired. A single axial slice group was
chosen at 50 % distance from knee to hip joint space. Two
three dimensional (3D) gradient echo sequences with dif-
ferent TE for in-phase and opposed-phase imaging were
acquired (30 slices, TR = 20 ms, TE1 = 2.45 ms,
TE2 = 3.68 ms, flip angle = 15, acquisition time
2:49 min). A field of view of 400 9 400 mm and a
384 9 384 matrix were used yielding 1 mm in plane res-
olution with 3 mm slice thickness. Two saturation bands
were placed above the slab to avoid inflow artefacts from
arterial blood. The protocol was completed within
15–20 min dependent on the amount of localizer angula-
tion necessary.
For every patient, regions of interest (ROI) were drawn
in thigh muscles (Fig. 1) and care was taken to areas of
chemical shift artefact. Three ROIs were chosen to evalu-
ate the knee extensors (quadriceps), knee flexors (ham-
strings) and adductor muscle groups. All ROIs were drawn
by one co-author (M.S.) and independently checked for
quality on raw images and calculated maps by a radiologist
with 5 years experience in neuromuscular imaging (A.F.)
and by one physicist performing the evaluations (M.G.).
All MRI evaluations were performed blinded to clinical
status and MFM measurements.
In the two-point Dixon method [13], two images at
identical positions are acquired such that water and fat
protons are in-phase and opposed-phase, respectively.
A combination of these images yields water (w) and fat
(f) images. Relative fat content maps were generated from
the pixelwise fat fraction given by f/(f ? w). ROIs were
placed on the maps and the mean fat content was calculated
for each muscle group.
Independent ambulation was assessed according to the
method proposed by Vuillerot et al. [4], who calculated a
hypothetical score of 25 % for the D1 subscale of the
MFM as cutoff point to establish loss of independent
ambulation.
Statistical analysis was performed by the corresponding
author using JMP 8.0.2 (SAS Institute, Cary, NC, USA).
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Correlations were calculated using Spearman’s rank coef-
ficient. Categorical data were compared using Fischer’s
exact test.
Results
We included 20 DMD patients aged 5–23 (median
10.2 years, mean 11.2 years). The average MFM was
65.3 % (Table 1) and showed a strong negative correlation
to age (r2 = 0.60, p \ 0.001), with most prominent chan-
ges (r2 = 0.61, p \ 0.001) in the D1 component, measur-
ing standing position and transfer, whereas the D3
component, assessing distal motor function showed no
correlation (r2 = 0.01, p = 0.75). Assessment of inde-
pendent ambulation according to Vuillerot corresponded
perfectly to patient reports: no patient with a D1 compo-
nent below 25 % reported independent ambulation, while
all patients above 25 % showed some degree of indepen-
dent ambulation.
Average cross sectional area of the ROI was 6,248 mm2
(599–11,618 mm2) for the quadriceps, 3,374 mm2
(521–9,955 mm2) for the hamstrings and 2,450 mm2
(467–5,758 mm2) for the adductors.
Fat fractions of the major muscle groups were increased
(Table 1). These changes were symmetrical in each patient
as indicated by a correlation of 0.99 between the legs.
There was a positive correlation between fat fractions and
age of 0.61 and 0.64 for the right and left quadriceps,
respectively. The corresponding values for the hamstrings
were 0.55 and 0.57, and for the adductors 0.51 and 0.53,
indicating a moderate correlation (p \ 0.001 for all cor-
relations). While the average increase over all patients
could be calculated with high confidence (small dotted
lines in 2b), variability between patients resulted in larger
confidence intervals for each individual patient (large
dotted lines in 2).
In the MFM scale, ambulation is mainly assessed with
the D1 component, which showed a high negative
correlation to the fat fractions in the left and right quad-
riceps of 0.93 and 0.91 (Fig. 2a) and of 0.86 and 0.85 in the
left and right hamstrings, respectively (p \ 0.001). When a
50 % cutoff for the fat fraction was used, loss of ambula-
tion could be predicted with a sensitivity of 100 %, and a
specificity of 91 and 100 % for the left and right leg,
respectively (p \ 0.0001). One patient lost ambulation
(D1 = 10 %) although he presented with a left quadriceps
fat fraction of 54 %.
Average increase of fatty replacement for the individual
muscle groups could be calculated as:
Fig. 1 A mean fat fraction map
calculated from two-point
Dixon MRI in % is overlayed
with typical ROIs in a patient
with extensive fatty
replacement. Quadriceps in red
and yellow, hamstrings in green/
turquoise, adductors in blue/
purple on the right/left,
respectively
Table 1 Clinical and MRI data
Mean Median Standard
deviation
Minimum Maximum
MFM total
(%)
65.3 73.0 27.0 19.8 93.75
D1 (%) 42.4 44.9 39.2 0 92.3
D2 (%) 79.2 97.2 30.0 13.9 100
D3 (%) 84.0 85.7 13.9 42.8 100
FF right
quadriceps
(%)
38.9 39.0 28.6 6.9 77.7
FF left
quadriceps
(%)
40.1 44.9 28.5 7.6 79.0
FF right
hamstrings
(%)
42.1 41.5 29.0 8.7 79.7
FF left
hamstrings
(%)
41.5 37.2 29.1 8.3 79.9
FF right
adductors
(%)
35.6 21.8 25.6 7.9 81
FF left
adductors
(in %)
37.1 28.7 24.9 9.5 80.8
Motor function measurements (MFM) total values, and D1, D1 and
D3 subscales as well as mean fat fractions (FF) of the three major
muscle groups (quadriceps, hamstrings, adductors) for both legs
J Neurol (2013) 260:969–974 971
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Right quadriceps ¼ 17:7 þ 5:08  Age MRI 1
Left quadriceps ¼ 17:4 þ 5:15  Age MRI 1
Right hamstrings ¼ 12:1 þ 4:86  Age MRI 1
Left hamstrings ¼ 14:1 þ 4:98  Age MRI 1
Right adductors ¼ 10:7 þ 4:15  Age MRI 1
Left adductors ¼ 8:97 þ 4:13  Age MRI 1
translating into an annual 5 % increase in the fat content of
the quadriceps and hamstrings starting from an age
between 3 and 4 years.
Discussion
Due to its high prevalence and rapid progression, DMD was
used as a model for imaging in muscular dystrophies early
on. Huang et al. [7] measured T1 and T2 values in the anterior
tibial muscle and found increased T2 times and reduced T1
times in patients with DMD as compared to healthy controls.
Liu et al. [11] developed a visual grading system, measuring
the number of involved muscles per region and found an
excellent correlation to functional parameters.
Kinali et al. compared visual analyses of fatty replace-
ment in the calves of 34 DMD patients to histologic
analyses of the extensor digitorum brevis. They found a
correlation between the semiquantitative MRI score and
age as well as a correlation to the time since loss of
independent ambulation [10]. No quantitative analysis was
performed.
Quantitative MRI
While visual scores show a high inter-reader variability,
qMRI is expected to be more reproducible and therefore
more objective and more reliable for the assessment of
fatty atrophy in DMD. Excellent reproducibility of qMRI
was demonstrated in healthy volunteers [14] as well as in
patients with oculopharyngeal muscle dystrophy [8, 15]. In
the latter case, qMRI was also more sensitive in detecting
progressive changes than clinical evaluation and visual
analysis of MRI scans. While qMRI is influenced by
exercise, the changes introduced even with exercise until
muscular fatigue are far below the changes we observed in
our study collective [16]. Kim et al. [17] examined T2
maps and visual fatty atrophy in the gluteus muscles in 11
boys with DMD before and after 12 months of steroid
treatment and found increased fatty atrophy in two patients
and increasing T2 values in five patients, stable results in
two and decreasing T2 values in four patients. T2 values
are increased by fatty replacement and by inflammatory
changes. This might explain the heterogeneous results by
Kim et al., as steroid treatment can influence both com-
ponents in variable degrees. We therefore consider the fat
fraction to be a more robust and reliable parameter, espe-
cially for long-term disease monitoring. The correlation of
the MFM score to fatty atrophy found in our study was
higher than correlations of T2 values to clinical function
scores or the Gowers test [18]. Alternatively, separate
evaluation of T2 values for the fat and water components
might provide additional information but require longer
scanning time [19], which might be difficult in children
with DMD. Gaeta et al. examined 20 patients with DMD
using two-point Dixon fat measurements in several muscles
of the thigh and hip. They found the highest FF in the
gluteus maximus and adductor magnus muscle and the
lowest in the semitendinosus muscle [20]. Fat fractions
correlated to patient age, as well as to the MRC score for
muscular strength and the timed Gowers test for standing
up. As only patients who were independently ambulant and
cooperative were included, they were unable to correlate
their data to the loss of ambulation [20].
Fig. 2 Correlation of the fat fraction of the right quadriceps to the D1
component of the MFM (a) and to age of the patient (b). Large dotted
lines indicate 95 % confidence intervals for individual patients. Small
dotted lines in b indicate 95 % confidence intervals for the calculated
correlation
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Predicting the loss of ambulation
Vuillerot et al. [4] used the MFM score to predict loss of
ambulation in patients with DMD and estimated that a total
score of 70 % and a D1 subscore of 40 % will predict loss
of ambulation within 1 year. Variability in their data,
however, was too large to make predictions over longer
periods. Clinical scores also have the disadvantage of being
dependent on patient cooperation. In contrast, qMRI offers
an observer independent measurement which is highly
repeatable and can be performed on most clinical scanners.
The coefficient of repeatability of 0.9 % calculated by
Sinclair et al. [9] for FF measurement with MRI indicates
that even small trials can detect a differences as small as
2 % in FF with a high statistical power.
For our study we proposed a cutoff value of 50 % for
loss of ambulation, as semiquantitative evaluations in
orthopaedic patients indicate irreparable damage with a fat
fraction above 50 % indicated by a Goutallier grade of 3 or
above [21]. We calculated an average increase in muscular
fat of about 5 % per year. This would mean that the time
until loss of ambulation could be approximated as:
ðTime to loss of ambulation)
¼ ð50% current fat content in %Þ=5%=year:
According to this calculation, a difference in fat content
of 2 % should be detectable after 6 months. In addition it
might be possible to calculate the increased time to loss of
ambulation with novel therapies. If for example, FF with a
novel therapy would increase by 1 % over a 6-month trial
period (as compared to 2.5 % during the natural course),
this would indicate that a 5-year old boy receiving this
treatment could remain ambulatory until an age of
15 years.
However, greater variability between patients and the
known variability in the clinical course indicate that age at
disease onset, or muscular content at disease onset or the
progression of fatty atrophy have some degree of inter-
individual variability. Future trials should therefore be
performed with repeated measurements on individual
patients to assess the rate of increase in muscle fat content
individually.
Using an individual progression rate, qMRI might also
provide the necessary biomarker for small group or indi-
vidual patient trials [22, 23], as it is noninvasive and has a
high reproducibility.
Limitations
Our study has limitations, the major being the lack of a
control group to evaluate change in fatty atrophy over time.
Data from previous trials, however, demonstrate that the
overall fat fraction in healthy volunteers is stable [15].
Another limitation arises from the relatively small number
of patients included in our study. A further limitation lies in
potential confounding effects of the two-point Dixon
method. As only two measurements are used, field inho-
mogeneities and phase shifts might introduce a potential
error in the calculated relative fat content. One possible
solution is the use of a third measurement, the so-called
three-point Dixon method, which was not available on our
scanner at the time of this study. We used an implemen-
tation for the two-point Dixon technique that accounts for
phase errors from magnetic field inhomogeneities.
A potential issue of gradient echo-based two-point Dixon
imaging is that T1 and T2* relaxation may cause inaccu-
rate fat and water images [24], This leads to a potential
overestimation of low FF and an underestimation of high
FF by the two-point Dixon method.
In conclusion, we were able to correlate fat fractions in
the major muscle groups of the thigh to age and clinical
parameters of physical abilities in DMD patients using
qMRI. This allowed an estimation of the natural course of
the disease and estimation of the remaining time until loss
of ambulation based on a single qMRI scan. This might be
a helpful prognostic tool in the prediction of loss of
ambulation and might also serve as an outcome measure in
future therapeutic trials. A longitudinal study, however,
should be performed to validate these findings.
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